ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 84

Benefits of Treat-to-Target Guideline Compliance in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis

Martin J. Bergman1, James W. Shaw2, Mary A. Cifaldi3, Annie Guerin4, Pooja Chopra5 and James Signorovitch5, 1Taylor Hospital, Ridley Park, PA, 2Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, 3Abbott Laboratories, Abbott Park, IL, 4Analysis Group, Inc., Montreal, QC, Canada, 5Analysis Group, Inc., Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Clinical practice guidelines, economics and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: To achieve clinical remission/low disease activity in patients with rheumatoid arthritis (RA), the treat-to-target (T2T) guidelines recommend frequent disease monitoring through patient-rheumatologist interactions. The economic implications of treating to target have not been fully quantified.  This study aimed to estimate the effects of compliance with T2T recommendations regarding patient follow-up on health care resource utilization (HRU) and medical service costs in RA patients newly initiated on a disease-modifying anti-rheumatic drug (DMARD).

Methods: Patients ≥18 years old with ≥2 RA diagnoses and ≥1 prescription fill for a DMARD that was preceded by a rheumatologist encounter (within 7 days) were identified from the MarketScan® Commercial Claims and Encounters database (1/2000 to 9/2011).  A patient’s index date was randomly selected among all new DMARD initiation dates with ≥3 months of continuous enrollment before and ≥15 months after that date. Patients with a follow-up rheumatologist visit within 90 days of the index date were defined as compliant, while all others were classified as noncompliant.  HRU and costs (measured from a payer’s perspective in 2010 US dollars) were measured over a 1-year period starting 90 days after the index date.  Adjusted all-cause HRU and medical service costs were compared between compliant and noncompliant patients using multivariable regression.

Results: A total of 15,103 RA patients were selected with 10,739 (71.1%) being designated as compliant.  The average age was 49.9 years, and 23.2% were male.  After adjusting for potential confounding, compliant patients exhibited significantly fewer inpatient admissions and inpatient days, fewer emergency room (ER) visits, and less use of other medical services but significantly more outpatient visits than noncompliant patients.  Consequently, compliant patients had significantly lower adjusted inpatient costs but significantly higher adjusted outpatient costs than noncompliant patients.  The inpatient cost reduction offset the increase in outpatient costs such that there was no significant difference between the two cohorts with respect to aggregate adjusted medical service costs.

Conclusion: RA patients benefit from being followed in a manner consistent with T2T guidelines.  Notably, they exhibit fewer inpatient visits with lower length of stay and lower ER utilization without incurring an increase in medical service costs due to more frequent follow-up with a rheumatologist.  However, more research is needed to assess the impact of rigorous follow-up on patient quality of life.


Disclosure:

M. J. Bergman,
None;

J. W. Shaw,

Abbott Laboratories,

3;

M. A. Cifaldi,

Abbott Laboratories,

3,

Abbott Laboratories,

1;

A. Guerin,

Abbott Laboratories,

5;

P. Chopra,

Abbott Laboratories,

5;

J. Signorovitch,

Abbott Laboratories,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/benefits-of-treat-to-target-guideline-compliance-in-patients-with-rheumatoid-arthritis-a-retrospective-claims-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology